LOS ANGELES , May 12, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fluence Energy, Inc. ("Fluence" or "the Company") (NASDAQ: FLNC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 29, 2023, and February 10, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before May 12, 2025.

LOS ANGELES , May 12, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ibotta, Inc. ("Ibotta" or "the Company") (NYSE: IBTA) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents issued in connection with its initial public offering ("IPO") conducted on April 18, 2024, are encouraged to contact the firm before June 16, 2025.

CVE Q1 earnings gain on higher contributions from the Oil Sands, Conventional, and Offshore units. However, revenues witness a year-over-year decline.

Investors interested in Intuitive Machines stock may let it go before tomorrow, considering its premium valuation and unfavorable Zacks rank.

JACK's second-quarter fiscal 2025 performance is likely to have been hurt by dismal traffic and macroeconomic pressures.

Agenus (AGEN) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $1.61. This compares to loss of $3.04 per share a year ago.

WidePoint (WYY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Oatly Group (OTLY) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Puma Biotech (PBYI) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Sezzle Inc. (SEZL) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

TTEC (TTEC) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Aveanna (AVAH) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Whirlpool Corporation reported solid Q1 results in a turbulent operating environment, continuing cost take out. President Trump's tariffs provide Whirlpool a cost edge against previously cost-advantaged Asian competition. Tariffs are a short-term headwind for Whirlpool, but a clear long-term tailwind. Whirlpool's 8.8% dividend should be sustained, making WHR stock attractive. While coming with significant risks, I currently estimate 60% upside to $127.6.

LOS ANGELES , May 12, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ: SANA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 17, 2023 and November 4, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before May 20, 2025.

LOS ANGELES , May 12, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against TFI International Inc. ("TFI" or "the Company") (NYSE: TFII) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 26, 2024 and February 19, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before May 13, 2025.

Strategic Move Bolsters MySize's B2B & B2C Portfolio and Aligns with Upcoming EU Regulatory Requirements AIRPORT CITY, Israel , May 12, 2025 /PRNewswire/ -- MySize, Inc. (NASDAQ: MYSZ), a leader in AI-driven retail solutions and omnichannel e-commerce platforms, today announced the acquisition by its newly-formed, wholly-owned subsidiary in Spain, New Percentil, S.L., of key assets of Percentil, a leading managed marketplace for second-hand fashion, with operations across Spain, France, Germany, and Italy, following insolvency proceedings in Spain of Percentil's former owner.

LOS ANGELES , May 12, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zenas BioPharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents issued in connection with its initial public offering ("IPO") conducted on September 13, 2024, are encouraged to contact the firm before June 16, 2025.

Brokers have more insights into stocks and the macroeconomic backdrop. One must follow broker rating upgrades to pick stocks like DIS, CTSH and EXE.

Women's health device maker, Hologic HOLX, slashed its earnings forecast for the full fiscal 2025, even as the latest second-quarter results topped expectations. The revenue target of $4.05-$4.10 billion remained the same as stated during the February earnings call, reflecting the $100 million cut from the initial guidance.

Surgery Partners (SGRY) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.10 per share a year ago.